4D Pharma Plc (LON:DDDD)


Founded in 2014, 4D Pharma Plc, formerly known as Schosween 18 Limited, is a UK-based pharmaceutical company business engaged in developing various projects targeting new therapeutic area.  The company is developing Live Biotherapeutic Products (LBPs), which is a novel class drug derived from the human microbiome for gastrointestinal disease, cancer, respiratory disease and condition of the central nervous system (CNS). The company leverages rational, mechanism-driven hypotheses, driven by its MicroRx platform and focuses on understanding mechanisms of action and the interaction of its LBPs with host biology to fulfill the unmet needs of patient. The company has positioned itself to transform the industry with four clinical programs delivering data and a various development programs in existing new areas progressing towards the clinic. It portfolio consist of over 65 patent families granted in US, Europe and other major market and encompassing more than 1,000 granted patents covering its core products. The company’s shares are listed on the London Stock Exchange as LON: DDDD.

The company’s highly productive discovery platform, MicroRx cross-examines its proprietary library of bacterial isolates for therapeutic functionality by recognizing strains which has significant effects on the host and by targeting diseases that are driven by pathways which match the host response profile of strain. In 2016 the company also launched MicroDx, a microbiome profiling platform which analyzes the microbiome to treat the patients with its Live Biotherapeutics and is currently used in its clinical trials in US and Europe.  The company’s additional development programs include GI, immune-oncology, autoimmune, respiratory and CNS disease. The company’s ongoing four clinical stage programs include IBS, immune-oncology, asthma and IBD.

Contact Information

company address 9 Bond Court LS1 2JZ United Kingdom

company phone+44.113.8950130

company websitehttps://www.4dpharmaplc.com/

Similar Companies